Abstract: A server case includes a case, a drawer body, and a adjustable device. The drawer body is received in the case. The adjustable device includes a first end, a second end, and a adjustable structure. The second end is connected to the drawer body, the adjustable structure is connected to the first end and the second end, and a distance between the first end and the second end is changeable. The drawer body received in the case is moved until at least a part of the drawer body is located outside the case, to change the distance between the first end and the second end.

Abstract: A semiconductor die package is provided. The semiconductor die package includes a semiconductor die and a package substrate supporting and electrically connected to the semiconductor die. The semiconductor die has a corner. The package substrate includes several conductive lines, and one of the conductive lines under the corner of the semiconductor die includes a first line segment and a second line segment connected to the first line segment. The first line segment is linear and extends in a first direction. The second line segment is non-linear and has a varying extension direction.

Abstract: An apparatus for countercurrent exchange, including: a conduit, including: a side wall; an inner space; an air outlet disposed on a first end of the conduit; a liquid miniaturization device disposed in the inner space of the conduit near the air outlet, wherein the liquid miniaturization device is used to spray a liquid in a liquid direction; an air intake disposed on the side wall near a second end of the conduit; and a reservoir portion disposed in the inner space near the second end of the conduit for storing the liquid; a pneumatic conveyor connected with the air intake for introducing air into the conduit along an air flow direction; and a pumping device connected with the reservoir portion by a first tube, wherein the liquid direction is opposite to the air flow direction in the conduit.

Abstract: A server case includes a case, a drawer body, and a adjustable device. The drawer body is received in the case. The adjustable device includes a first end, a second end, and a adjustable structure. The second end is connected to the drawer body, the adjustable structure is connected to the first end and the second end, and a distance between the first end and the second end is changeable. The drawer body received in the case is moved until at least a part of the drawer body is located outside the case, to change the distance between the first end and the second end.

Abstract: The present invention relates to a method able to enhance survival and functionality of anti-tumor or anti-viral immune cells through overexpression of Akt molecules in the cells. Akt signaling prevented the expression of immune checkpoints and therefore rescued antigen-specific cytotoxic T lymphocytes from exhaustion in immunosuppressive microenvironment.

Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.

Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.

Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.

Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

Abstract: The present invention relates to methods of making human anti-HMGB1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions in HMGB1 associated-neuropathy.

Abstract: This invention relates to an immunosuppressive cell, and methods of obtaining the cell and using the cell. The immunosuppressive cell is obtained by culturing a precursor cell in a medium that contains a GRO chemokine.

Abstract: In order to provide necessary information for the production of complete human monoclonal antibodies capable of human CD152 (CTLA-4) binding, the primary structures of heavy and light chains have been elucidated. The novel amino acid sequence of identified heavy and light chains are derived from VH3 and V? germline genes, respectively. Antibodies comprising such novel structures cause specific binding to soluble recombinant human CD152 as well as to activated human peripheral T cells, where the expression of CD152 has been elevated.

Abstract: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

Abstract: The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.

Abstract: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

Abstract: The present invention provides a CTLA-4 non-blocking agent of a complete human antibody nature, thus is non-immunogenic in a human. The immunoassay method using such a non-blocking agent measures the CTLA-4 content in a sample of a human subject. The present invention further provides a novel method for isolating human regulatory T cells. The resultant enriched and depleted cellular populations are useful in treating or ameliorating of human diseases.

Abstract: A method of fabricating a color filter substrate is provided. First, a transparent substrate having a display region, a peripheral region and a buffer region is provided. Next, a shielding pattern layer is formed in the peripheral region of the transparent substrate, and a color filter layer is formed in the display region of the transparent substrate. Further, at least one buffer pattern is formed in the buffer region.

Abstract: A method for obtaining agonist, antagonist and inverse agonist, to a given physiological receptor is disclosed. For the method, use is made of in silico design synthetic immunogens, which are caused to act in vitro on human lymphocyte-containing cell populations. A preferred receptor is human CD152, particularly the regions of CDR1, CDR2 and CDR3 that elicit antibodies serving as antagonist, inverse agonist and agonist, respectively. Also provided is a method in the treatment of human peripheral lymphocytes for use in the screening of CD152 ligands that yield pharmacological effects.

Abstract: In a cluster system comprising at least two nodes connected via a communication network and having a name and a host weight assigned to it, a method is implemented comprising the steps of inspecting the communication link, determining which node has to be shut down after a failure, creating an advertisement report for the node to be shut down, sending the advertisement report to at least one node of the cluster system, calculating a delay time depending on the weight of the first node and sending the shut down command to the node for which a failure report was received. In one embodiment of the invention the advertisement reports include a master node, which allows identifying and specifying the surviving subcluster. The method will send shut down signals to those nodes of a subcluster with lower weight than the surviving subcluster. A failsafe mechanism is implemented.